Literature DB >> 22402109

Multifocal carcinoma in situ of the upper tract is associated with high risk of bladder cancer recurrence.

Evanguelos Xylinas, Michael Rink, Vitaly Margulis, Pierre Karakiewicz, Giacomo Novara, Shahrokh F Shariat.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22402109     DOI： 10.1016/j.eururo.2012.02.042

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


× No keyword cloud information.
  22 in total

1.  Intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinomas: predictors and impact on subsequent oncological outcomes from a national multicenter study.

Authors:  Evanguelos Xylinas; Pierre Colin; François Audenet; Véronique Phe; Luc Cormier; Olivier Cussenot; Alain Houlgatte; Gilles Karsenty; Franck Bruyère; Thomas Polguer; Alain Ruffion; Antoine Valeri; François Rozet; Jean-Alexandre Long; Marc Zerbib; Morgan Rouprêt
Journal:  World J Urol       Date:  2012-09-30       Impact factor: 4.226

2.  Early repeated ureteroscopy within 6-8 weeks after a primary endoscopic treatment in patients with upper tract urothelial cell carcinoma: preliminary findings.

Authors:  Luca Villa; Jonathan Cloutier; Julien Letendre; Achilles Ploumidis; Andrea Salonia; Jean-Nicolas Cornu; Francesco Montorsi; Olivier Traxer
Journal:  World J Urol       Date:  2015-12-23       Impact factor: 4.226

3.  Tumor evolution and progression in multifocal and paired non-invasive/invasive urothelial carcinoma.

Authors:  Joshua I Warrick; Daniel H Hovelson; Anmol Amin; Chia-Jen Liu; Andi K Cani; Andrew S McDaniel; Venkata Yadati; Michael J Quist; Alon Z Weizer; J Chad Brenner; Felix Y Feng; Rohit Mehra; Catherine S Grasso; Scott A Tomlins
Journal:  Virchows Arch       Date:  2014-12-11       Impact factor: 4.064

4.  Liquid Biopsy Landscape in Patients with Primary Upper Tract Urothelial Carcinoma.

Authors:  Stephanie N Shishido; Alireza Ghoreifi; Salmaan Sayeed; George Courcoubetis; Amy Huang; Brandon Ye; Sankalp Mrutyunjaya; Inderbir S Gill; Peter Kuhn; Jeremy Mason; Hooman Djaladat
Journal:  Cancers (Basel)       Date:  2022-06-18       Impact factor: 6.575

Review 5.  EZH2 in Bladder Cancer, a Promising Therapeutic Target.

Authors:  Mónica Martínez-Fernández; Carolina Rubio; Cristina Segovia; Fernando F López-Calderón; Marta Dueñas; Jesús M Paramio
Journal:  Int J Mol Sci       Date:  2015-11-13       Impact factor: 5.923

6.  Predictive value of clinicopathological markers for the metachronous bladder cancer and prognosis of upper tract urothelial carcinoma.

Authors:  Chenchen Feng; Lujia Wang; Guanxiong Ding; Qiang Ding; Zhongwen Zhou; Haowen Jiang; Zhong Wu
Journal:  Sci Rep       Date:  2014-02-06       Impact factor: 4.379

7.  The Influence of Tumor Size on Oncologic Outcomes for Patients with Upper Tract Urothelial Carcinoma after Radical Nephroureterectomy.

Authors:  Xiaohong Su; Dong Fang; Xuesong Li; Gengyan Xiong; Lei Zhang; Han Hao; Yanqing Gong; Zheng Zhang; Liqun Zhou
Journal:  Biomed Res Int       Date:  2016-12-14       Impact factor: 3.411

Review 8.  Upper tract urothelial carcinoma: a different disease entity in terms of management.

Authors:  Jeffrey J Leow; Kian Tai Chong; Steven L Chang; Joaquim Bellmunt
Journal:  ESMO Open       Date:  2017-01-24

9.  High expression of KPNA2 defines poor prognosis in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy.

Authors:  Bentao Shi; Boxing Su; Dong Fang; Yuan Tang; Gengyan Xiong; Zhongqiang Guo; Qun He; Xinyu Yang; Wei Zhao; Yinglu Guo; Xuesong Li; Liqun Zhou
Journal:  BMC Cancer       Date:  2015-05-09       Impact factor: 4.430

10.  Positive urinary fluorescence in situ hybridization indicates poor prognosis in patients with upper tract urothelial carcinoma.

Authors:  Bao Guan; Yicong Du; Xiaohong Su; Zhenpeng Cao; Yifan Li; Yonghao Zhan; Ding Peng; Gengyan Xiong; Dong Fang; Yi Ding; Shiming He; Yanqing Gong; Qun He; Xuesong Li; Liqun Zhou
Journal:  Oncotarget       Date:  2018-01-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.